Neoadjuvant Toripalimab Combined with Gemcitabine and Cisplatin in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (neotgp01): an Open Label, Single-Arm, Phase Ib Clinical Trial
Journal of Experimental & Clinical Cancer Research(2022)
Key words
Head and neck squamous cell carcinoma,Immunotherapy,Neoadjuvant treatment,Pathological response rate
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined